Market Overview:
The global ezetimibe market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of obesity and other lifestyle diseases, rising awareness about cholesterol management, and the launch of novel products. By type, the market is segmented into 10 mg tablet and Type II. The 10 mg tablet segment is expected to account for a larger share of the market in 2018. By application, the adult segment is expected to dominate the market in 2018. However, with increasing awareness about cholesterol management among children (10-17 years), this segment is projected to grow at a higher CAGR during the forecast period.
Product Definition:
Ezetimibe is a cholesterol-lowering medication that blocks the absorption of cholesterol in the small intestine. It is used to lower LDL (bad) cholesterol levels and to prevent heart disease. Ezetimibe is important because it helps reduce the risk of heart disease, which is the leading cause of death in the United States.
10 mg tablet:
10 mg tablet is used for the treatment of high cholesterol and triglyceride levels in the body. High cholesterol and triglyceride levels are linked to heart disease, stroke, coronary artery disease, peripheral vascular disease, and other heart conditions. Heart diseases have become a major cause of death globally over the last three decades.
Type II:
Type II diabetes is also known as juvenile or insulin-dependent diabetes. In this type of diabetes, the body does not produce enough insulin to enable cells to absorb glucose from the blood. The most common symptoms include frequent urination, increased urine sugar (glucose) level and fatigue. Type II can be distinguished from type I by a blood test that measures hemoglobin A1C levels.
Application Insights:
The application segment includes adult and children. In 2017, the adult segment held the largest share of over 70%. The high prevalence of diabetes in North America and Europe is expected to drive product demand in this region. According to a study published by WHO, it was estimated that approximately 30% of people aged 60 years or above have hypertension which requires treatment with medication. Thus, rising incidence rate for heart diseases coupled with growing awareness regarding proper medication will boost market growth during the forecast period for ezetimibe among adults.
The pediatric segment is expected to grow at fastest CAGR from 2018 to 2030 owing to increasing awareness about obesity among children as well as adolescents along with easy access to products through online pharmacies.
Regional Analysis:
North America was the largest market in 2017 and accounted for a revenue share of over 35%. The U.S., as well as Canada, are among the top 10 countries with the highest number of patients suffering from heartburn or acid reflux disease (ARRD). Moreover, high adoption of ezetimibe-based drugs coupled with favorable reimbursement scenario is expected to drive regional growth during the forecast period.
Asia Pacific is anticipated to be one of fastest growing regions due to increasing awareness about lifestyle changes and rising geriatric population prone to chronic diseases such as cardiovascular disorders, diabetes, and kidney stones. In addition, improving healthcare infrastructure in emerging economies including India & China will boost industry expansion over the next eight years.
Growth Factors:
- Increasing prevalence of obesity and diabetes: The increasing prevalence of obesity and diabetes is a major growth driver for the Ezetimibe market. Obesity is a risk factor for developing type 2 diabetes, and both conditions are associated with an increased risk of cardiovascular disease. Ezetimibe is effective in reducing LDL cholesterol levels, which can help to reduce the risk of cardiovascular events in patients with type 2 diabetes or metabolic syndrome.
- Rising awareness about the benefits of cholesterol-lowering medications: There has been a growing awareness among healthcare professionals and patients about the benefits of cholesterol-lowering medications such as Ezetimibe. This has led to an increase in demand for these drugs, driving market growth.
- Growing number of product approvals: The number of product approvals for Ezetimibe has been growing over the past few years, providing a boost to market growth. In 2017, two new products were approved by the US FDA – Zetia tablets (Ezetrol) and Vytorin tablets (ezalutamide). These new products are expected to drive market growth over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Ezetimibe Market Research Report
By Type
10 mg tablet, Type II
By Application
Adult, Children(10-17 years)
By Companies
Merck, Teva, Zydus Pharmaceuticals, Amneal Pharmaceuticals, Alkem Laboratories, APOTEX, Sandoz, Glenmark Pharmaceuticals, Mylan Pharmaceuticals, Aurobindo Pharma, Accord Healthcare
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global Ezetimibe Market Report Segments:
The global Ezetimibe market is segmented on the basis of:
Types
10 mg tablet, Type II
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Adult, Children(10-17 years)
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- Teva
- Zydus Pharmaceuticals
- Amneal Pharmaceuticals
- Alkem Laboratories
- APOTEX
- Sandoz
- Glenmark Pharmaceuticals
- Mylan Pharmaceuticals
- Aurobindo Pharma
- Accord Healthcare
Highlights of The Ezetimibe Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 10 mg tablet
- Type II
- By Application:
- Adult
- Children(10-17 years)
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Ezetimibe Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Ezetimibe is a cholesterol-lowering medication that works by blocking the absorption of cholesterol from the intestines. This can lead to lower levels of LDL (bad) cholesterol in the blood.
Some of the major companies in the ezetimibe market are Merck, Teva, Zydus Pharmaceuticals, Amneal Pharmaceuticals, Alkem Laboratories, APOTEX, Sandoz, Glenmark Pharmaceuticals, Mylan Pharmaceuticals, Aurobindo Pharma, Accord Healthcare.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Ezetimibe Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Ezetimibe Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Ezetimibe Market - Supply Chain
4.5. Global Ezetimibe Market Forecast
4.5.1. Ezetimibe Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Ezetimibe Market Size (000 Units) and Y-o-Y Growth
4.5.3. Ezetimibe Market Absolute $ Opportunity
5. Global Ezetimibe Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Ezetimibe Market Size and Volume Forecast by Type
5.3.1. 10 mg tabletII
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Ezetimibe Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Ezetimibe Market Size and Volume Forecast by Application
6.3.1. Adult
6.3.2. Children(10-17 years)
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Ezetimibe Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Ezetimibe Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Ezetimibe Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Ezetimibe Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Ezetimibe Demand Share Forecast, 2019-2029
9. North America Ezetimibe Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Ezetimibe Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Ezetimibe Market Size and Volume Forecast by Application
9.4.1. Adult
9.4.2. Children(10-17 years)
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Ezetimibe Market Size and Volume Forecast by Type
9.7.1. 10 mg tabletII
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Ezetimibe Demand Share Forecast, 2019-2029
10. Latin America Ezetimibe Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Ezetimibe Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Ezetimibe Market Size and Volume Forecast by Application
10.4.1. Adult
10.4.2. Children(10-17 years)
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Ezetimibe Market Size and Volume Forecast by Type
10.7.1. 10 mg tabletII
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Ezetimibe Demand Share Forecast, 2019-2029
11. Europe Ezetimibe Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Ezetimibe Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Ezetimibe Market Size and Volume Forecast by Application
11.4.1. Adult
11.4.2. Children(10-17 years)
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Ezetimibe Market Size and Volume Forecast by Type
11.7.1. 10 mg tabletII
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Ezetimibe Demand Share, 2019-2029
12. Asia Pacific Ezetimibe Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Ezetimibe Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Ezetimibe Market Size and Volume Forecast by Application
12.4.1. Adult
12.4.2. Children(10-17 years)
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Ezetimibe Market Size and Volume Forecast by Type
12.7.1. 10 mg tabletII
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Ezetimibe Demand Share, 2019-2029
13. Middle East & Africa Ezetimibe Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Ezetimibe Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Ezetimibe Market Size and Volume Forecast by Application
13.4.1. Adult
13.4.2. Children(10-17 years)
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Ezetimibe Market Size and Volume Forecast by Type
13.7.1. 10 mg tabletII
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Ezetimibe Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Ezetimibe Market: Market Share Analysis
14.2. Ezetimibe Distributors and Customers
14.3. Ezetimibe Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Merck
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Teva
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Zydus Pharmaceuticals
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Amneal Pharmaceuticals
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Alkem Laboratories
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. APOTEX
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Sandoz
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Glenmark Pharmaceuticals
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Mylan Pharmaceuticals
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Aurobindo Pharma
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Accord Healthcare
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
